V
Veena Shankaran
Researcher at Fred Hutchinson Cancer Research Center
Publications - 108
Citations - 6267
Veena Shankaran is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 24, co-authored 77 publications receiving 4178 citations. Previous affiliations of Veena Shankaran include Seattle Cancer Care Alliance & University of Washington.
Papers
More filters
Journal ArticleDOI
IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers,Jared Lunceford,Michael Nebozhyn,Erin Murphy,Andrey Loboda,David Ross Kaufman,Andrew Albright,Jonathan D. Cheng,S. Peter Kang,Veena Shankaran,Sarina Anne Piha-Paul,Jennifer H. Yearley,Tanguy Y. Seiwert,Antoni Ribas,Terrill K. McClanahan +14 more
TL;DR: The T cell–inflamed GEP contained IFN-&ggr;–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit.
Journal ArticleDOI
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara,Mustafa Ozguroglu,Yung-Jue Bang,Maria Di Bartolomeo,Mario Mandalà,Min-Hee Ryu,Lorenzo Fornaro,Tomasz Olesinski,Christian Caglevic,Hyun Cheol Chung,Kei Muro,Eray Goekkurt,Wasat Mansoor,Raymond S. McDermott,Einat Shacham-Shmueli,X. Chen,Carlos Alberto Mayo,S. Peter Kang,Atsushi Ohtsu,Charles S. Fuchs,Guillermo Lerzo,Juan Manuel O'Connor,Guillermo Mendez,James Lynam,Niall C. Tebbutt,Mark Wong,Andrew Strickland,Chris Karapetis,David Goldstein,Paul Vasey,Jean-Luc Van Laethem,Eric Van Cutsem,Scott R. Berry,Mark Vincent,Bettina Muller,Felipe Rey,Angela Zambrano,Joaquin Guerra,Merete Krogh,Lene Baeksgaard,Mette Karen Yilmaz,Anneli Elme,Andrus Magi,Paivi Auvinen,Tuomo Alanko,Markus Moehler,Volker Kunzmann,Thomas Seufferlein,Peter C. Thuss-Patience,Thomas Hoehler,Georg Martin Haag,Salah-Eddin Al-Batran,Hugo Castro,Karla Lopez,Mynor Aguilar Vasquez,Mario Sandoval,Ka On Lam,Sinead Cuffe,Cathy Kelly,Ravit Geva,Ayala Hubert,Alex Beny,Baruch Brenner,Aprile Giuseppe,Alfredo Falcone,Evaristo Maiello,Rodolfo Passalacqua,Vincenzo Montesarchio,Hiroki Hara,Keisho Chin,Tomohiro Nishina,Yoshito Komatsu,Nozumo Machida,Shuichi Hironaka,Taroh Satoh,Takao Tamura,Naotaoshi Sugimoto,Haruhiko Cho,Yashushi Omuro,Ken Kato,Masahiro Goto,Ichinosuke Hyodo,Kazuhiro Yoshida,Hideo Baba,Taito Esaki,Junji Furuse,Wan Zamaniah Wan Mohammed,Carlos Hernandez Hernandez,Juan Casas Garcia,Adriana Dominguez Andrade,Katriona Clarke,Geir Hjortland,Nils Glenjen,Tomasz Kubiatowski,Jassem Jacek,Marek Z. Wojtukiewicz,Sergey Alexandrovich Lazarev,Yuri Lancukhay,Sergey Afanasayev,Vladimir Moiseyenko,Vladimir Kostorov,Svetlana Protsenko,Vadim Shirinkin,Dina Sakaeva,Natalia Fadeeva,Wei Peng Yong,Chau Hsien Matthew Ng,Barbara Robertson,Bernardo Rapaport,Graham Cohen,Lydia Dreosti,Paul Ruff,Conrad Jacobs,Gregory Landers,Waldemar Szpak,Sang-Young Roh,Jeeyun Lee,Yeul Hong Kim,Hyun Cheol Chung,Maria Alsina Maqueda,Federico Longo Munoz,Andres Cervantes Aguilar,Enrique Aranda Aguilar,Pilar Garcia Alfonso,Fernando Rivera,Jaime Feliu Batle,Roberto Pazo Cid,Kun-Huei Yeh,Jen-Shi Chen,Yee Chao,Chia Jui Yen,Oguz Kara,Suayib Yalcin,Daniel Hochhauser,Ian Chau,Al B. Benson,Veena Shankaran,Walid Shaib,Philip A. Philip,Vivek Sharma,Robert J. Siegel,Weijing Sun,Zev A. Wainberg,Ben George,Andrea J. Bullock,Samuel Myrick,Josephine Faruol,Richard M. Siegel,Timothy V. Larson,Carlos Becerra,Suresh Ratnam,Donald A. Richards,Stephen L. Riche +152 more
TL;DR: Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher and had a better safety profile than pac litaxel.
Journal ArticleDOI
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro,Hyun Cheol Chung,Veena Shankaran,Ravit Geva,Daniel V.T. Catenacci,Shilpa Gupta,Joseph Paul Eder,Talia Golan,Dung T. Le,Barbara Burtness,Autumn J. McRee,Chia-Chi Lin,Kumudu Pathiraja,Jared Lunceford,Kenneth Emancipator,Jonathan Juco,Minori Koshiji,Yung-Jue Bang +17 more
TL;DR: In this population of patients with recurrent or metastatic PD-L1-positive gastric cancer, pembrolizumab had a manageable toxicity profile and promising antitumour activity, warranting further study in phase 2 and 3 trials.
Journal ArticleDOI
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Scott D. Ramsey,Aasthaa Bansal,Catherine R. Fedorenko,David K. Blough,Karen A. Overstreet,Veena Shankaran,Polly A. Newcomb +6 more
TL;DR: Severe financial distress requiring bankruptcy protection after cancer diagnosis appears to be a risk factor for mortality, according to Cox proportional hazards models.
Journal ArticleDOI
Risk Factors for Financial Hardship in Patients Receiving Adjuvant Chemotherapy for Colon Cancer: A Population-Based Exploratory Analysis
TL;DR: A significant proportion of patients undergoing adjuvant chemotherapy for stage III colon cancer may experience financial hardship, despite having health insurance coverage, and younger age, lower income, and unemployment or disability were most closely associated with treatment nonadherence.